Drug intelligence / Profile preview

Antox (Pharma Nord)

Development stage
Unknown
Lead developer
Pharma Nord
Modality
Small Molecules
Administration
Oral
01

Overview

Antox (also referred to as Antox version 1.2) is an oral multi-ingredient antioxidant preparation developed by Pharma Nord for the management of pain in chronic pancreatitis. The formulation is a combination of selenium, beta-carotene, d-alpha-tocopherol acetate (vitamin E), ascorbic acid (vitamin C), and the amino acid methionine. It is designed to act broadly as an antioxidant, targeting oxidative stress and reactive oxygen species (ROS) that are hypothesized to contribute to pancreatic damage and pain in chronic pancreatitis. While early crossover trials suggested some quality-of-life benefits, the larger randomized, double-blind, placebo-controlled ANTICIPATE trial demonstrated that Antox did not significantly reduce pain or improve quality of life in patients with predominantly alcoholic chronic pancreatitis, despite successfully increasing blood antioxidant levels.

Brand names
Antox
Other names
Antox 1.2Antox1.2Antox-1.2
02

Targets

LOO• (Lipid peroxyl radical)

Beyond the preview

Go deeper on Antox (Pharma Nord).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antox (Pharma Nord).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call